News

Investigators observe dramatic decrease in treatment burden seen in OPTIC study.

Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.

A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden

The modified red blood cell therapy RTX-240 demonstrated promising efficacy and a favorable safety profile in patients with relapsed/refractory solid tumors.

The FDA has granted VX-880 a fast track designation as a potential treatment for patients with type 1 diabetes.

An experimental safety switch incorporated into chimeric antigen receptor (CAR) T-cell therapy reduced the severity of the treatment’s side effects in an early-phase trial.

Idecabtagene vicleucel induced progression-free survival up to 20 months and a complete response in one-third of patients with multiple myeloma who had relapsed multiple times and had received at least 3 previous lines of treatment.

The lentiviral vector used to create LentiGlobin was deemed a very unlikely cause of AML in a patient with sickle cell disease.

Christopher D'Angelo, MD, discusses emerging CAR T-cell therapies in the space, as well as in follicular lymphoma, and the challenges with using a 5-drug regimen.

The FDA has granted an RMAT designation to valoctocogene roxaparvovec for hemophilia A.

A phase 2 clinical trial has been initiated to evaluate Descartes-11, an mRNA CAR T-cell therapy, as a consolidative therapy in patients with newly diagnosed, high-risk multiple myeloma who have residual disease after induction therapy.

The FDA has granted a fast track designation to PBFT02, PBKR03, and PBGM01, which are intended as treatments for patients with various rare CNS disorders.

The 2-stage study is an open-label, 2-stage clinical trial designed to evaluate safety and dose-escalation (stage 1) and safety and efficacy (stage 2) of surgically delivered AXO-AAV-GM2.

Data from the phase 2 ZUMA-5 trial supported the approval of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with follicular lymphoma in the third-line setting.

Orchard Therapeutics released its plans for 2021, which included the launch of OTL-200 (Libmeldy) in Europe and development of an FDA submission strategy in the United States.

Treatment may facilitate sight in end-stage retinitis pigmentosa.

Pathogenic germline variants identified among children and young adults with rhabdomyosarcoma suggest that all children with RMS should undergo germline sequencing to utilize available surveillance guidelines and inform potential gene-specific therapy options.

Baseline diabetic retinopathy severity is an important predictor of its progression in patients.

Topline data from the phase 3 REVEAL 1 study show VGX-3100 led to higher rates of high-grade squamous intraepithelial lesions regression and HPV-16 and/or HPV-18 clearance compared with placebo.

UniQure plans to file etranacogene dezaparvovec with the FDA for hemophilia B in March, pending a positive resolution to a clinical hold placed in December.

More than 2 years after treatment, some of the patients with relapsed/refractory multiple myeloma have yet to see a relapse. An FDA decision on the therapy is expected within a month.

High-dose chemotherapy and transplant remains the second-line standard of care for the majority of patients with relapsed/refractory diffuse large B-cell lymphoma; however, CAR T-cell therapy and other novel agents, which have transformed the third-line setting, may offer alternative and more personalized second-line options in the coming years.

Rocket Pharmaceuticals has summarized multiple major milestones for its 5 gene therapies from 2020 and provided a forecast and outlook for what is expected to be a banner year for the organization.

CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.

Preliminary evidence pinpoints classical causes for AML in patient treated with LentiGlobin in a phase 1/2 study for sickle cell disease.

Treatment with chimeric antigen receptor T cells has induced unprecedented overall response rates and complete response rates in patients with relapsed/refractory B cell malignancies.

Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.

Sanofi has entered a new agreement with SIRION Biotech to develop tissue-selective AAV vectors for novel gene therapies.